JMP Securities analyst Constantine Davides lowered the firm’s price target on AMN Healthcare (AMN) to $34 from $47 and keeps an Outperform rating on the shares amid a broader research note on Healthcare Services. The firm reduced its 2025 EBITDA estimate to $235M from $250M on slightly more conservative operating margin assumptions and sees 2026 revenue of $2.66B on EBITDA of $255M, and its more conservative multiple is the result of continued near-term secular pressures within healthcare staffing, the analyst says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMN:
Questions or Comments about the article? Write to editor@tipranks.com